State & Local News
Eli Lilly Invests in Huntsville Manufacturing Facility
March 16, 2026
Eli Lilly announced a $6 billion investment to build a new pharmaceutical manufacturing facility in Huntsville, Alabama, representing the largest capital investment in the state's history. This facility will focus on domestic production of small molecule synthetic and peptide medicines, including oral GLP-1 drugs, and is expected to create 450 jobs. Senior Vice President Eric Hahn, who leads Eli Lilly's global pharmaceutical manufacturing expansion, will highlight this development at the Birmingham Business Journal Manufacturing Summit on June 11, 2026.
- This investment signals significant growth in pharmaceutical manufacturing capacity in Alabama, emphasizing the state's strategic importance for domestic drug production.
- Procurement professionals should note the scale and scope of this project as it may generate substantial contracting and supply chain opportunities in pharmaceutical manufacturing and related services.
- Contractors and suppliers specializing in manufacturing infrastructure, equipment, and pharmaceutical production technologies may find new business prospects tied to this facility.
- The focus on domestic production aligns with broader government and industry trends toward supply chain resilience and onshoring of critical pharmaceutical manufacturing.
Hahn leads efforts to expand and modernize Eli Lillyโs global pharmaceutical manufacturing network.
— Eric Hahn
Vendors
Eli Lilly and Co.
Contracts
$6 billion
Locations
Sources
- Eli Lilly executive Eric Hahn to speak BBJ manufacturing summit - Birmingham Business Journal · The Business Journals · Mar 16